Connecting Chemistry with Society

Effective Collaboration Strategies to Drive Innovation in Drug Discovery and Development (#179)

Pharmaceutical industry and academic biomedical research alike focus a lot of effort toward the discovery of new drugs. The undertaking of revamping this expensive, difficult, and most often inefficient process is challenging, and filled with various obstacles. This session will address how innovation still thrives despite the challenges faced and decisions made during the product development process. We will discuss how large pharma, biotech and start-ups make go/no-go decisions; how scientific and legal teams collaborate during the development process; some of the major challenges faced during the development process; and tactics employed for overcoming those challenges. This session will also highlight how technological innovation and court cases affect patent drafting, and enforcement, and consequently pharma and biomedical research. Another aspect of this session will be the interplay with CROs. Within this session we will also discuss licensing-in/out that is growing in the US as well as Japan, China and South Korea. Recent growing interests in drug discovery of pharmaceutical companies in the Pacific Rim pushed them to license in good leads or preclinical candidates from academia or national labs. At the same time they have a huge interest in licensing out their products in Phase1 or 2 to big pharmas or foreign biotechs. Perspectives from start-ups, biotech, large pharma and CROs will be presented with both scientific and managerial view points.
Last update: Dec 28, 2015